Earnings
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Here’s a look at the eight most profitable biopharma companies around the world. Profitability, in this case, refers to net income, as opposed to total revenue or sales.
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Silverback is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave it with more cash reserves.
Ginkgo Bioworks reported its 2021 financials today, and the $1.7 billion of stock-based compensation caught everyone’s attention.
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.
After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.
Sanofi and IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.
The acquisition of Sunosi transforms Axsome into a global commercial business that will support its operations as it moves closer to launching its treatments for depression and migraine.
Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.
PRESS RELEASES